Company Analysis

Indaptus Therapeutics, Inc. (INDP)

Nasdaq: INDP · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2021
Grade4.3
◀ Past 4.0● Present 2.0▶ Future 6.4
6 est.

Who runs Indaptus Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Dai Junyi
Chief Executive Officer. First filing Apr 2026, latest Apr 2, 2026, 0 filings in all.
Officers reporting now
6
of 11 people with a filing in the last fifteen months
Directors reporting now
5
21 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Dai JunyiChief Executive OfficerApr 2026Apr 2, 2026none
Lazar David E.Co-Chief Executive OfficerDec 2025Mar 24, 2026none
Meckler Jeffrey ACo-Chief Executive OfficerAug 2021Feb 13, 2026none
Sassi NirChief Financial OfficerAug 2021Dec 29, 2025none
Linscott Walt AddisonChief Operating OfficerAug 2021Dec 29, 2025none
Newman Michael JamesCSO and DirectorAug 2021Dec 29, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Lu QinglaidirectorApr 2026Apr 20, 2026none
Jabbour Jerome DdirectorFeb 2026Feb 27, 2026none
Mcmurdo Matthew CharlesdirectorFeb 2026Feb 26, 2026none
Ben-Tzvi AvrahamdirectorDec 2025Jan 22, 2026none
Natan DaviddirectorJan 2026Jan 22, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Sino Lion Ventures Ltd10% ownerApr 2026Apr 2, 2026none
Yao Yun10% ownerApr 2026Apr 2, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton INDP · research, not advice